Home Merck Announces CHMP Issues Positive Opinion for Investigational Antibiotic SIVEXTRO (tedizolid phosphate)
 

Keywords :   


Merck Announces CHMP Issues Positive Opinion for Investigational Antibiotic SIVEXTRO (tedizolid phosphate)

2015-01-26 14:30:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of the investigational antibiotic SIVEXTRO (tedizolid phosphate) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. Merck acquired SIVEXTRO as a part of its purchase, through a subsidiary, of Cubist Pharmaceuticals, Inc. Language: English Contact: Media:Pam Eisele, 267-305-3558Jennifer Baird, 781-860-1282orInvestor:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: issues positive opinion announces

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
14.11
14.115
14.11MTGfoil
14.11
14.11sw14000XH 8000
14.11katie
14.11EX 330 HP SAR
14.11 M1
More »